scholarly article | Q13442814 |
P50 | author | Bruce L. Innis | Q39447629 |
P2093 | author name string | Green S | |
Ennis FA | |||
Raengsakulrach B | |||
Vaughn DW | |||
Nisalak A | |||
Kalayanarooj S | |||
Nimmannitya S | |||
Rothman AL | |||
Suntayakorn S | |||
Endy TP | |||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | virus | Q808 |
antibody | Q79460 | ||
Dengue virus | Q476209 | ||
P304 | page(s) | 2-9 | |
P577 | publication date | 2000-01-01 | |
P1433 | published in | Journal of Infectious Diseases | Q4051141 |
P1476 | title | Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity | |
P478 | volume | 181 |
Q33722079 | 2nd International External Quality Control Assessment for the Molecular Diagnosis of Dengue Infections |
Q61806871 | A 20-Gene Set Predictive of Progression to Severe Dengue |
Q40546528 | A Blunted Blood Plasmacytoid Dendritic Cell Response to an Acute Systemic Viral Infection Is Associated with Increased Disease Severity |
Q58992219 | A Comprehensive Study on the 2012 Dengue Fever Outbreak in Kolkata, India |
Q24276099 | A Dengue Fever Viremia Model in Mice Shows Reduction in Viral Replication and Suppression of the Inflammatory Response after Treatment with Antiviral Drugs |
Q64257465 | A Mismatch-Tolerant Reverse Transcription Loop-Mediated Isothermal Amplification Method and Its Application on Simultaneous Detection of All Four Serotype of Dengue Viruses |
Q27486786 | A Mouse-Passaged Dengue Virus Strain with Reduced Affinity for Heparan Sulfate Causes Severe Disease in Mice by Establishing Increased Systemic Viral Loads |
Q40288450 | A Role for RNA Viruses in the Pathogenesis of Burkitt's Lymphoma: The Need for Reappraisal |
Q37139005 | A bispecific antibody effectively neutralizes all four serotypes of dengue virus by simultaneous blocking virus attachment and fusion |
Q34309568 | A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro |
Q40061824 | A dose-response study in mice of a tetravalent vaccine candidate composed of domain III-capsid proteins from dengue viruses |
Q38128110 | A model international partnership for community-based research on vaccine-preventable diseases: the Kamphaeng Phet-AFRIMS Virology Research Unit (KAVRU). |
Q27305445 | A model of DENV-3 infection that recapitulates severe disease and highlights the importance of IFN-γ in host resistance to infection |
Q39611340 | A mouse monoclonal antibody against dengue virus type 1 Mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity |
Q24288926 | A novel dengue virus detection method that couples DNAzyme and gold nanoparticle approaches |
Q36505563 | A novel inhibitor of dengue virus replication that targets the capsid protein |
Q38884987 | A peptide inhibitor derived from the conserved ectodomain region of DENV membrane (M) protein with activity against dengue virus infection |
Q36523070 | A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults |
Q40180446 | A plasmid-based reporter system for live cell imaging of dengue virus infected cells |
Q28475036 | A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults |
Q34288828 | A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients |
Q28241909 | A rapid immunization strategy with a live-attenuated tetravalent dengue vaccine elicits protective neutralizing antibody responses in non-human primates |
Q38658737 | A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone |
Q33647936 | A replication study confirms the association of GWAS-identified SNPs at MICB and PLCE1 in Thai patients with dengue shock syndrome |
Q90560585 | A review of Dengvaxia®: development to deployment |
Q38184218 | A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available |
Q39847833 | A simple method for evaluating dengue vaccine effectiveness in mice based on levels of viremia caused by intraperitoneal injection of infected culture cells |
Q33919503 | A single amino acid in nonstructural protein NS4B confers virulence to dengue virus in AG129 mice through enhancement of viral RNA synthesis |
Q36607295 | A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial |
Q33988937 | A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial |
Q35082478 | A small molecule inhibitor of dengue virus type 2 protease inhibits the replication of all four dengue virus serotypes in cell culture |
Q33430557 | A survey of the 2014 dengue fever epidemic in Guangzhou, China |
Q37679389 | A systematic approach to virus-virus interactions. |
Q40553373 | A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4. |
Q34412344 | A variant in the CD209 promoter is associated with severity of dengue disease |
Q40470757 | Activated peripheral lymphocytes with increased expression of cell adhesion molecules and cytotoxic markers are associated with dengue fever disease. |
Q57185107 | Activation of Peripheral T Follicular Helper Cells During Acute Dengue Virus Infection |
Q35727211 | Activation of TLR2 and TLR6 by Dengue NS1 Protein and Its Implications in the Immunopathogenesis of Dengue Virus Infection |
Q33774668 | Acute dengue virus 2 infection in Gabonese patients is associated with an early innate immune response, including strong interferon alpha production |
Q91212064 | Adaptive immune responses to primary and secondary dengue virus infections |
Q34359759 | Adenovirus delivered short hairpin RNA targeting a conserved site in the 5' non-translated region inhibits all four serotypes of dengue viruses |
Q38982873 | Age and clinical dengue illness |
Q41929185 | Age-associated differences in clinical manifestations and laboratory parameters during a dengue virus type 4 outbreak in Argentina |
Q40967611 | Age-dependent variation in innate immune responses to porcine epidemic diarrhea virus infection in suckling versus weaned pigs |
Q33945431 | Age-specificity of clinical dengue during primary and secondary infections |
Q40040951 | Alpha-mangostin inhibits both dengue virus production and cytokine/chemokine expression |
Q47548291 | Alphavirus-induced hyperactivation of PI3K/AKT directs pro-viral metabolic changes. |
Q33379078 | Alternate hypothesis on the pathogenesis of dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS) in dengue virus infection |
Q39838739 | Alternative infectious entry pathways for dengue virus serotypes into mammalian cells |
Q27473379 | American Genotype Structures Decrease Dengue Virus Output from Human Monocytes and Dendritic Cells |
Q35681101 | An Epitope-Substituted DNA Vaccine Improves Safety and Immunogenicity against Dengue Virus Type 2. |
Q28114617 | An Evidence-Based Algorithm for Early Prognosis of Severe Dengue in the Outpatient Setting |
Q27481478 | An Immunogenic and Protective Alphavirus Replicon Particle-Based Dengue Vaccine Overcomes Maternal Antibody Interference in Weanling Mice |
Q27487842 | An analysis of the subtypes of dengue fever infections in Barbados 2003–2007 by reverse transcriptase polymerase chain reaction |
Q34353489 | An emerging role for the anti-inflammatory cytokine interleukin-10 in dengue virus infection. |
Q40579802 | An improved endothelial barrier model to investigate dengue haemorrhagic fever |
Q24606493 | An in-depth analysis of original antigenic sin in dengue virus infection |
Q38605194 | Analysis of cell-mediated immune responses in support of dengue vaccine development efforts |
Q35168403 | Antibodies against immature virions are not a discriminating factor for dengue disease severity |
Q38825543 | Antibodies are not required to a protective immune response against dengue virus elicited in a mouse encephalitis model |
Q26700094 | Antibody avidity following secondary dengue virus type 2 infection across a range of disease severity |
Q39002738 | Antibody recognition of the dengue virus proteome and implications for development of vaccines |
Q90167450 | Antibody-Dependent Dengue Virus Entry Modulates Cell Intrinsic Responses for Enhanced Infection |
Q25708015 | Antibody-Dependent Enhancement of Dengue Virus Infection in Primary Human Macrophages; Balancing Higher Fusion against Antiviral Responses |
Q34550268 | Antibody-dependent enhancement infection facilitates dengue virus-regulated signaling of IL-10 production in monocytes. |
Q47592202 | Antibody-dependent enhancement of severe dengue disease in humans |
Q52652259 | Antiviral Activity of Novel Quinoline Derivatives against Dengue Virus Serotype 2. |
Q38118461 | Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions |
Q38286716 | Antiviral therapy: a perspective |
Q97420738 | Application of Next-Generation Sequencing to Reveal How Evolutionary Dynamics of Viral Population Shape Dengue Epidemiology |
Q90001651 | Arabidopsis thaliana and Pseudomonas Pathogens Exhibit Stable Associations over Evolutionary Timescales |
Q43019710 | Arguments for live flavivirus vaccines |
Q28119393 | Assay optimization for molecular detection of Zika virus |
Q28730914 | Assessing the potential of a candidate dengue vaccine with mathematical modeling |
Q36131935 | Association of FcγRIIa Polymorphism with Clinical Outcome of Dengue Infection: First Insight from Pakistan |
Q35618935 | Association of human immune response to Aedes aegypti salivary proteins with dengue disease severity |
Q33581167 | Asunaprevir Evokes Hepatocytes Innate Immunity to Restrict the Replication of Hepatitis C and Dengue Virus |
Q34372767 | Asymmetry in the presence of migration stabilizes multistrain disease outbreaks |
Q36331893 | Asymptomatic humans transmit dengue virus to mosquitoes |
Q40457185 | Attenuating characteristics of DEN-2 PDK53 in flavivirus-naïve peripheral blood mononuclear cells. |
Q40215702 | Atypical Manifestations of Dengue Fever (DF) - Where Do We Stand Today? |
Q56762940 | Autoimmune features caused by dengue fever: a case report |
Q33405382 | Autoimmunity in dengue pathogenesis |
Q36950883 | B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts |
Q35567408 | B-cell responses during primary and secondary dengue virus infections in humans |
Q42991886 | Barriers to preclinical investigations of anti-dengue immunity and dengue pathogenesis |
Q26746185 | Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment |
Q38255509 | Biochemistry and medicinal chemistry of the dengue virus protease |
Q40040211 | Biodistribution and safety of a live attenuated tetravalent dengue vaccine in the cynomolgus monkey |
Q39254939 | Biological functions of fucose in mammals |
Q37829510 | Biosensors and rapid diagnostic tests on the frontier between analytical and clinical chemistry for biomolecular diagnosis of dengue disease: a review |
Q33363361 | Bleeding and other presentations in Thai patients with dengue infection |
Q58792953 | Blockade of dengue virus entry into myeloid cells by endocytic inhibitors in the presence or absence of antibodies |
Q37195614 | Breaking the symmetry: immune enhancement increases persistence of dengue viruses in the presence of asymmetric transmission rates |
Q40303816 | CD16(+) natural killer cells play a limited role against primary dengue virus infection in tamarins |
Q40539803 | Can hematocrit and platelet determination on admission predict shock in hospitalized children with dengue hemorrhagic fever? A clinical observation from a small outbreak |
Q40061338 | Case Management of Dengue: Lessons Learned |
Q24276104 | Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model |
Q34500247 | Cellular and cytokine correlates of severe dengue infection |
Q40241605 | Cellulose-based diagnostic devices for diagnosing serotype-2 dengue fever in human serum |
Q38121757 | Challenges for the formulation of a universal vaccine against dengue. |
Q38931854 | Challenges in the Laboratory Diagnosis and Management of Dengue Infections |
Q36373989 | Changing pattern of dengue virus serotypes in Thailand between 2004 and 2010. |
Q40485854 | Chaotic desynchronization of multistrain diseases |
Q34277290 | Characteristics of a dengue outbreak in a remote pacific island chain--Republic of The Marshall Islands, 2011-2012 |
Q37372604 | Characteristics of mild dengue virus infection in Thai children |
Q39909329 | Characterization of dengue virus infections in a sample of patients suggests unique clinical, immunological, and virological profiles that impact on the diagnosis of dengue and dengue hemorrhagic fever |
Q55021139 | Characterization of recent and minimally passaged Brazilian dengue viruses inducing robust infection in rhesus macaques. |
Q27469872 | Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice |
Q41928393 | Chymase is a Predictive Biomarker of Dengue Hemorrhagic Fever in Pediatric and Adult Patients |
Q28551786 | Cissampelos pareira Linn: Natural Source of Potent Antiviral Activity against All Four Dengue Virus Serotypes |
Q30577169 | Climate change, population immunity, and hyperendemicity in the transmission threshold of dengue |
Q33757489 | Clinical and virological characteristics of dengue in Surabaya, Indonesia |
Q33980158 | Clinical and virological factors influencing the performance of a NS1 antigen-capture assay and potential use as a marker of dengue disease severity |
Q40329907 | Clinical applicability of single-tube multiplex reverse-transcriptase PCR in dengue virus diagnosis and serotyping. |
Q35954329 | Clinical evaluation of dengue and identification of risk factors for severe disease: protocol for a multicentre study in 8 countries |
Q27473482 | Clinical features and pitfalls in the laboratory diagnosis of dengue in travellers |
Q57091901 | Clinical manifestations of dengue in relation to dengue serotype and genotype in Malaysia: A retrospective observational study |
Q35220195 | Clinical outcome and genetic differences within a monophyletic Dengue virus type 2 population |
Q90443656 | Clinical, Virological, and Cytokine Profiles of Children Infected with Dengue Virus during the Outbreak in Southern Vietnam in 2017 |
Q34195851 | Clinical, epidemiological and virological features of Dengue virus infections in Vietnamese patients presenting to primary care facilities with acute undifferentiated fever. |
Q34478823 | Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo |
Q35979011 | Commercial dengue rapid diagnostic tests for point-of-care application: recent evaluations and future needs? |
Q27980447 | Comparative Analysis of Dengue and Zika Outbreaks Reveals Differences by Setting and Virus |
Q49920855 | Comparative immunogenicity of preparations of yeast-derived dengue oral vaccine candidate |
Q33943479 | Comparing dengue and chikungunya emergence and endemic transmission in A. aegypti and A. albopictus |
Q56342856 | Comparing the effectiveness of different strains of Wolbachia for controlling chikungunya, dengue fever, and zika |
Q40574326 | Comparison of four reverse transcription-polymerase chain reaction procedures for the detection of dengue virus in clinical specimens |
Q37287595 | Comparison of the mosquito inoculation technique and quantitative real time polymerase chain reaction to measure dengue virus concentration |
Q26314512 | Competitive advantage of a dengue 4 virus when co-infecting the mosquito Aedes aegypti with a dengue 1 virus |
Q38965572 | Competitive inhibitor of cellular α-glucosidases protects mice from lethal dengue virus infection |
Q39611315 | Complement-independent dengue virus type 1 infection-enhancing antibody reduces complement-dependent and -independent neutralizing antibody activity |
Q36086736 | Complete genome sequence of a dengue virus serotype 4 strain isolated in Guangdong, China |
Q40282430 | Complete genome sequencing and evolutionary analysis of dengue virus serotype 1 isolates from an outbreak in Kerala, South India |
Q35781863 | Comprehensive mapping infection-enhancing epitopes of dengue pr protein using polyclonal antibody against prM |
Q64101350 | Concurrent infections of dengue virus serotypes in Bali, Indonesia |
Q37647431 | Conditions of the household and peridomicile and severe dengue: a case-control study in Brazil |
Q91807708 | Considering Genomic and Immunological Correlates of Protection for a Dengue Intervention |
Q27486156 | Construction of an infectious cDNA clone for a Brazilian prototype strain of dengue virus type 1: Characterization of a temperature-sensitive mutation in NS1 |
Q27469921 | Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine |
Q55119556 | Contributions from the silent majority dominate dengue virus transmission. |
Q36804428 | Contributions of mast cells and vasoactive products, leukotrienes and chymase, to dengue virus-induced vascular leakage |
Q21562250 | Controlling dengue with vaccines in Thailand |
Q33415746 | Corticosteroids in the treatment of dengue shock syndrome |
Q40293590 | Cost of production of live attenuated dengue vaccines: a case study of the Instituto Butantan, Sao Paulo, Brazil |
Q27478185 | Cost-Effective Real-Time Reverse Transcriptase PCR (RT-PCR) To Screen for Dengue Virus followed by Rapid Single-Tube Multiplex RT-PCR for Serotyping of the Virus |
Q97078537 | Cost-efficiency analysis of voluntary vaccination against n-serovar diseases using antibody-dependent enhancement: a game approach |
Q36853974 | Coupled Heterogeneities and Their Impact on Parasite Transmission and Control |
Q40204571 | Critical role of Dengue Virus NS1 protein in viral replication |
Q27477511 | Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok |
Q35551374 | Cross-reactivity and expansion of dengue-specific T cells during acute primary and secondary infections in humans |
Q102372418 | Current Understanding of the Pathogenesis of Dengue Virus Infection |
Q35830864 | Current advances in dengue diagnosis |
Q33408300 | Current progress in dengue vaccines |
Q89988842 | Cytokine Expression in Dengue Fever and Dengue Hemorrhagic Fever Patients with Bleeding and Severe Hepatitis |
Q61803857 | Cytokine Signature Associated with Disease Severity in Dengue |
Q27485469 | Decision Tree Algorithms Predict the Diagnosis and Outcome of Dengue Fever in the Early Phase of Illness |
Q40310361 | Decreased peripheral dendritic cell numbers in dengue virus infection |
Q33894951 | Defective interfering viral particles in acute dengue infections |
Q27488750 | Defining the levels of secreted non-structural protein NS1 after West Nile virus infection in cell culture and mice |
Q34722528 | Dendritic cells in dengue virus infection: targets of virus replication and mediators of immunity |
Q29619772 | Dengue |
Q85327578 | Dengue |
Q91271250 | Dengue |
Q39190189 | Dengue Fever Presenting as Purtscher-like Retinopathy. |
Q33421872 | Dengue Fever outbreak in delhi, north India: a clinico-epidemiological study |
Q27489549 | Dengue Hemorrhagic Fever in Infants: Research Opportunities Ignored |
Q33423535 | Dengue Hemorrhagic Fever in a Japanese Traveler with Pre-existing Japanese Encephalitis Virus Antibody |
Q27491350 | Dengue Hemorrhagic Fever: The Sensitivity and Specificity of the World Health Organization Definition for Identification of Severe Cases of Dengue in Thailand, 1994–2005 |
Q40614639 | Dengue NS1-specific antibody responses: isotype distribution and serotyping in patients with Dengue fever and Dengue hemorrhagic fever |
Q40107607 | Dengue Patients with Early Hemorrhagic Manifestations Lose Coordinate Expression of the Anti-Inflammatory Cytokine IL-10 with the Inflammatory Cytokines IL-6 and IL-8. |
Q27491036 | Dengue Plaque Reduction Neutralization Test (PRNT) in Primary and Secondary Dengue Virus Infections: How Alterations in Assay Conditions Impact Performance |
Q33443486 | Dengue Symptoms Significance in Anti-Dengue Drug Development: Road Less Travelled |
Q27473511 | Dengue Type 3 Virus in Plasma Is a Population of Closely Related Genomes: Quasispecies |
Q24737469 | Dengue Virus Antibodies Enhance Zika Virus Infection |
Q27485628 | Dengue Virus Evolution and Virulence Models |
Q40044088 | Dengue Virus Glycosylation: What Do We Know? |
Q61795493 | Dengue Virus Immunity Increases Zika Virus-Induced Damage during Pregnancy |
Q35641205 | Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice. |
Q99726129 | Dengue and Zika Viruses: Epidemiological History, Potential Therapies, and Promising Vaccines |
Q35865823 | Dengue and soluble mediators of the innate immune system |
Q35625026 | Dengue epidemiology: virus epidemiology, ecology, and emergence |
Q34394784 | Dengue fever and dengue haemorrhagic fever: challenges of controlling an enemy still at large |
Q40597834 | Dengue fever: a review |
Q24803937 | Dengue fever: new paradigms for a changing epidemiology |
Q35599078 | Dengue haemorrhagic fever or dengue shock syndrome in children |
Q40389581 | Dengue haemorrhagic fever or dengue shock syndrome in children. |
Q33375242 | Dengue has a benign presentation in renal transplant patients: a case series |
Q40580494 | Dengue hemorrhagic fever epidemiology in Thailand: description and forecasting of epidemics |
Q33400164 | Dengue hemorrhagic fever in Trinidad and Tobago: a case for a conservative approach to platelet transfusion |
Q39590469 | Dengue human infection models supporting drug development |
Q38386336 | Dengue human infection models to advance dengue vaccine development |
Q27489388 | Dengue in Vietnamese Infants—Results of Infection‐Enhancement Assays Correlate with Age‐Related Disease Epidemiology, and Cellular Immune Responses Correlate with Disease Severity |
Q33389194 | Dengue in infants: an overview |
Q34766802 | Dengue in travelers: kinetics of viremia and NS1 antigenemia and their associations with clinical parameters |
Q33769927 | Dengue incidence in urban and rural Cambodia: results from population-based active fever surveillance, 2006-2008. |
Q58929555 | Dengue laboratory diagnosis: still some room for improvement |
Q91562400 | Dengue proteins with their role in pathogenesis, and strategies for developing an effective anti-dengue treatment: A review |
Q28656204 | Dengue research opportunities in the Americas |
Q24288861 | Dengue research: a bibliometric analysis of worldwide and Arab publications during 1872-2015 |
Q37270826 | Dengue serotype immune-interactions and their consequences for vaccine impact predictions |
Q35590821 | Dengue serotype-specific differences in clinical manifestation, laboratory parameters and risk of severe disease in adults, singapore |
Q40110519 | Dengue severity associated with age and a new lineage of dengue virus-type 2 during an outbreak in Rio De Janeiro, Brazil |
Q39555529 | Dengue specific immunoglobulins M, A, and E in primary and secondary dengue 4 infected Salvadorian children |
Q40045729 | Dengue subgenomic flaviviral RNA disrupts immunity in mosquito salivary glands to increase virus transmission |
Q36397156 | Dengue type 4 in Rio de Janeiro, Brazil: case characterization following its introduction in an endemic region |
Q35964754 | Dengue vaccine: priorities and progress |
Q37194772 | Dengue vaccines for travelers |
Q34367194 | Dengue vaccines: recent developments, ongoing challenges and current candidates |
Q34109652 | Dengue vaccines: state of the art. |
Q38960985 | Dengue vaccines: what we know, what has been done, but what does the future hold? |
Q34118200 | Dengue virus |
Q31110897 | Dengue virus NS1 enhances viral replication and pro-inflammatory cytokine production in human dendritic cells |
Q35002940 | Dengue virus NS5 inhibits interferon-alpha signaling by blocking signal transducer and activator of transcription 2 phosphorylation. |
Q40198181 | Dengue virus and host antibody: a dangerous balancing act. |
Q28353949 | Dengue virus antibodies enhance Zika virus infection |
Q36286276 | Dengue virus antibody database: Systematically linking serotype-specificity with epitope mapping in dengue virus |
Q96773997 | Dengue virus co-infections with multiple serotypes do not result in a different clinical outcome compared to mono-infections |
Q40300465 | Dengue virus infection in renal allograft recipients: a case series during 2010 outbreak |
Q34364315 | Dengue virus infection mediates HMGB1 release from monocytes involving PCAF acetylase complex and induces vascular leakage in endothelial cells |
Q38933520 | Dengue virus infection of erythroid precursor cells is modulated by both thalassemia trait status and virus adaptation |
Q40584645 | Dengue virus infection rate in field populations of female Aedes aegypti and Aedes albopictus in Singapore |
Q39214840 | Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection |
Q24522443 | Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression |
Q56396121 | Dengue virus non-structural protein 1: a pathogenic factor, therapeutic target, and vaccine candidate |
Q24645380 | Dengue virus pathogenesis: an integrated view |
Q39500287 | Dengue virus persists and replicates during storage of platelet and red blood cell units. |
Q39689692 | Dengue virus surveillance: the co-circulation of DENV-1, DENV-2 and DENV-3 in the State of Rio de Janeiro, Brazil. |
Q21558785 | Dengue virus targets the adaptor protein MITA to subvert host innate immunity |
Q27491021 | Dengue virus-induced hemorrhage in a nonhuman primate model |
Q40313566 | Dengue virus-specific CD4+ and CD8+ T lymphocytes target NS1, NS3 and NS5 in infected Indian rhesus macaques |
Q43037501 | Dengue virus: break-bone fever |
Q39237925 | Dengue virus: isolation, propagation, quantification, and storage |
Q27026302 | Dengue viruses - an overview |
Q35294150 | Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera |
Q91439247 | Dengue viruses infect human megakaryocytes, with probable clinical consequences |
Q35276730 | Dengue--quo tu et quo vadis? |
Q34125057 | Dengue. |
Q28298464 | Dengue: a continuing global threat |
Q43039633 | Dengue: a potential transfusion-transmitted disease |
Q35775955 | Dengue: an arthropod-borne disease of global importance |
Q27469692 | Dengue: an escalating problem |
Q28085044 | Dengue: an update on treatment options |
Q35896391 | Dengue: where are we today? |
Q34266774 | Detection and typing of viruses using broadly sensitive cocktail-PCR and mass spectrometric cataloging: demonstration with dengue virus |
Q27473489 | Detection of Dengue Virus Replication in Peripheral Blood Mononuclear Cells from Dengue Virus Type 2-Infected Patients by a Reverse Transcription-Real-Time PCR Assay |
Q40487410 | Detection of dengue virus serotype 3 by reverse transcription-polymerase chain reaction in Aedes aegypti (Diptera, Culicidae) captured in Manaus, Amazonas |
Q34834135 | Detection of higher levels of dengue viremia using FcγR-expressing BHK-21 cells than FcγR-negative cells in secondary infection but not in primary infection |
Q64099613 | Detection of post-vaccination enhanced dengue virus infection in macaques: An improved model for early assessment of dengue vaccines |
Q36669080 | Determination of viremia and concentration of circulating nonstructural protein 1 in patients infected with dengue virus in Mexico |
Q40135692 | Development and Evaluation of a SYBR Green-Based Real-Time Multiplex RT-PCR Assay for Simultaneous Detection and Serotyping of Dengue and Chikungunya Viruses |
Q35206695 | Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine |
Q64125827 | Development of Dengue-type NS1 ELISA for Rapid Detection and Differentiation of Dengue Serotypes during Early Infection |
Q40602299 | Development of a fluorogenic RT-PCR system for quantitative identification of dengue virus serotypes 1-4 using conserved and serotype-specific 3' noncoding sequences |
Q40153482 | Development of a pan-serotype reverse transcription loop-mediated isothermal amplification assay for the detection of dengue virus. |
Q27491049 | Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys |
Q38639091 | Development of a recombinant, chimeric tetravalent dengue vaccine candidate |
Q36971263 | Development of an internally controlled real-time reverse transcriptase PCR assay for pan-dengue virus detection and comparison of four molecular dengue virus detection assays |
Q27488073 | Development of real time PCR for detection and quantitation of dengue viruses |
Q38048849 | Diagnosis of dengue: an update |
Q27487547 | Diagnostic Accuracy of NS1 ELISA and Lateral Flow Rapid Tests for Dengue Sensitivity, Specificity and Relationship to Viraemia and Antibody Responses |
Q91927668 | Diagnostic Performance of Dengue Virus Envelope Domain III in Acute Dengue Infection |
Q27487941 | Difference between the Abilities of Human Fc Receptor-Expressing CV-1 Cells To Neutralize American and Asian Genotypes of Dengue Virus 2 |
Q40420543 | Differences in global gene expression in peripheral blood mononuclear cells indicate a significant role of the innate responses in progression of dengue fever but not dengue hemorrhagic fever |
Q35576590 | Differences in type I interferon signaling antagonism by dengue viruses in human and non-human primate cell lines |
Q57064402 | Different aspects of platelet evaluation in dengue: measurement of circulating mediators, ability to interact with the virus, the degree of activation and quantification of intraplatelet protein content |
Q27477546 | Differential Enhancement of Dengue Virus Immune Complex Infectivity Mediated by Signaling-Competent and Signaling-Incompetent Human Fc RIA (CD64) or Fc RIIA (CD32) |
Q34613581 | Differential expression of Toll-like receptors in dendritic cells of patients with dengue during early and late acute phases of the disease |
Q34259867 | Differential in vivo clearance and response to secondary heterologous infections by H2(b)-restricted dengue virus-specific CD8+ T cells |
Q35842455 | Differential proteomic analysis of virus-enriched fractions obtained from plasma pools of patients with dengue fever or severe dengue |
Q40236472 | Differential regulation of angiopoietin 1 and angiopoietin 2 during dengue virus infection of human umbilical vein endothelial cells: implications for endothelial hyperpermeability |
Q35790729 | Differential replicative ability of clinical dengue virus isolates in an immunocompetent C57BL/6 mouse model. |
Q40561635 | Differential susceptibility of Aedes aegypti to infection by the American and Southeast Asian genotypes of dengue type 2 virus |
Q35130239 | Differential susceptibility of two field aedes aegypti populations to a low infectious dose of dengue virus |
Q36048467 | Discovery and Validation of Prognostic Biomarker Models to Guide Triage among Adult Dengue Patients at Early Infection |
Q34640282 | Discovery and characterization of potential prognostic biomarkers for dengue hemorrhagic fever |
Q83227399 | Discrete viral E2 lysine residues and scavenger receptor MARCO are required for clearance of circulating alphaviruses |
Q33567787 | Disease Burden of Dengue in the Philippines: Adjusting for Underreporting by Comparing Active and Passive Dengue Surveillance in Punta Princesa, Cebu City |
Q34075602 | Displacement of the predominant dengue virus from type 2 to type 1 with a subsequent genotype shift from IV to I in Surabaya, Indonesia 2008-2010. |
Q40238069 | Distinct activation phenotype of a highly conserved novel HLA-B57-restricted epitope during dengue virus infection |
Q24318532 | Distinct antiviral roles for human 2',5'-oligoadenylate synthetase family members against dengue virus infection |
Q35922064 | Distribution of Dengue Virus Types 1 and 4 in Blood Components from Infected Blood Donors from Puerto Rico |
Q35252840 | Distribution of fitness in populations of dengue viruses |
Q91614285 | Diversity of infectious aetiologies of acute undifferentiated febrile illnesses in south and Southeast Asia: a systematic review |
Q37682895 | Domain III of the envelope protein as a dengue vaccine target |
Q27882968 | Drivers of Inter-individual Variation in Dengue Viral Load Dynamics |
Q38256785 | Drugs for dengue: a patent review (2010-2014). |
Q27472667 | Dynamic effects of antibody-dependent enhancement on the fitness of viruses |
Q35895444 | Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity |
Q27469477 | Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections |
Q41928069 | Early molecular correlates of adverse events following yellow fever vaccination |
Q24795851 | Eco-epidemiological analysis of dengue infection during an outbreak of dengue fever, India |
Q27473480 | Ecological and immunological determinants of dengue epidemics |
Q64237192 | Effect of freeze-dried Carica papaya leaf juice on inflammatory cytokines production during dengue virus infection in AG129 mice |
Q64098610 | Efficacy of geraniin on dengue virus type-2 infected BALB/c mice |
Q34630222 | Efficiency of dengue serotype 2 virus strains to infect and disseminate in Aedes aegypti |
Q34053409 | Elevated levels of cell-free circulating DNA in patients with acute dengue virus infection |
Q36146301 | Elevated levels of vitamin D and deficiency of mannose binding lectin in dengue hemorrhagic fever |
Q26825663 | Endothelial cells in dengue hemorrhagic fever |
Q29196526 | Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity |
Q47558474 | Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo |
Q24289012 | Epidemiological Scenario of Dengue in Brazil |
Q21131163 | Epidemiological risk factors associated with high global frequency of inapparent dengue virus infections |
Q40125629 | Epidemiology and characteristics of the dengue outbreak in Guangdong, Southern China, in 2014. |
Q35866928 | Epidemiology of Infant Dengue Cases Illuminates Serotype-Specificity in the Interaction between Immunity and Disease, and Changes in Transmission Dynamics |
Q27477735 | Etiology of interepidemic periods of mosquito-borne disease |
Q40527785 | Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine |
Q37723567 | Evaluation of Non-Structural Protein-1(NS1) positive patients of 2013 dengue outbreak in Khyber Pakhtunkhwa, Pakistan. |
Q27480925 | Evaluation of a Commercial Real-Time PCR Kit for Detection of Dengue Virus in Samples Collected during an Outbreak in Goiania, Central Brazil, in 2005 |
Q27488388 | Evaluation of an Epitope-Blocking Enzyme-Linked Immunosorbent Assay for the Diagnosis of West Nile Virus Infections in Humans |
Q26768523 | Evaluation of antiviral activities of Houttuynia cordata Thunb. extract, quercetin, quercetrin and cinanserin on murine coronavirus and dengue virus infection |
Q35350529 | Evaluation of commercially available diagnostic tests for the detection of dengue virus NS1 antigen and anti-dengue virus IgM antibody |
Q39346277 | Evaluation of diagnostic tests: dengue |
Q34761908 | Evaluation of host and viral factors associated with severe dengue based on the 2009 WHO classification |
Q34522384 | Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates. |
Q27485433 | Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers |
Q84957829 | Evaluation of the antiviral activity of orlistat (tetrahydrolipstatin) against dengue virus, Japanese encephalitis virus, Zika virus and chikungunya virus |
Q34075766 | Evaluation of the traditional and revised WHO classifications of Dengue disease severity |
Q28204656 | Evasion of innate and adaptive immunity by flaviviruses |
Q33609685 | Evasion of the human innate immune system by dengue virus |
Q40291127 | Eventual role of asymptomatic cases of dengue for the introduction and spread of dengue viruses in non-endemic regions |
Q40363094 | Evidence for inter- and intra-genotypic variations in dengue serotype 4 viruses representing predominant and non-predominant genotypes co-circulating in Thailand from 1977 to 2001. |
Q39565102 | Evolution of attenuating mutations in dengue-2 strain S16803 PDK50 vaccine and comparison of growth kinetics with parent virus |
Q39611325 | Expression of enhancing-activity-free neutralizing antibody against dengue type 1 virus in plasmid-inoculated mice |
Q26257542 | Extended Evaluation of Virological, Immunological and Pharmacokinetic Endpoints of CELADEN: A Randomized, Placebo-Controlled Trial of Celgosivir in Dengue Fever Patients |
Q34531142 | Factors influencing dengue virus isolation by C6/36 cell culture and mosquito inoculation of nested PCR-positive clinical samples |
Q38916168 | Fever after a stay in the tropics. Part 2: Common imported tropical diseases |
Q24289308 | Fever from the forest: prospects for the continued emergence of sylvatic dengue virus and its impact on public health |
Q64359207 | Fever in travellers returning from the tropics |
Q91913005 | Fever in travellers returning from the tropics |
Q31156754 | First experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies |
Q55519030 | Flavivirus serocomplex cross-reactive immunity is protective by activating heterologous memory CD4 T cells. |
Q35632639 | Fluorescently labeled dengue viruses as probes to identify antigen-specific memory B cells by multiparametric flow cytometry |
Q56877982 | Focus: Dengue |
Q40333405 | Frequency alterations in key innate immune cell components in the peripheral blood of dengue patients detected by FACS analysis |
Q24737418 | From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine |
Q34738972 | Full serotype- and group-specific NS1 capture enzyme-linked immunosorbent assay for rapid differential diagnosis of dengue virus infection |
Q35601805 | Functionality of dengue virus specific memory T cell responses in individuals who were hospitalized or who had mild or subclinical dengue infection |
Q28474384 | Gene expression patterns of dengue virus-infected children from nicaragua reveal a distinct signature of increased metabolism |
Q27478354 | Generation and Characterization of Monoclonal Antibodies against Dengue Virus Type 1 for Epitope Mapping and Serological Detection by Epitope-Based Peptide Antigens |
Q39273369 | Generation and characterization of potential dengue vaccine candidates based on domain III of the envelope protein and the capsid protein of the four serotypes of dengue virus. |
Q39126155 | Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage. |
Q37698942 | Generation of human single-chain variable fragment antibodies specific to dengue virus non-structural protein 1 that interfere with the virus infectious cycle |
Q34759091 | Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax). |
Q92416661 | Genetic risk for dengue hemorrhagic fever and dengue fever in multiple ancestries |
Q28943386 | Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1 |
Q33638451 | Genome-wide expression profiling deciphers host responses altered during dengue shock syndrome and reveals the role of innate immunity in severe dengue |
Q36172100 | Genome-wide patterns of intrahuman dengue virus diversity reveal associations with viral phylogenetic clade and interhost diversity |
Q28073351 | Genomic approaches for understanding dengue: insights from the virus, vector, and host |
Q45324483 | Geraniin extracted from the rind of Nephelium lappaceum binds to dengue virus type-2 envelope protein and inhibits early stage of virus replication. |
Q24736362 | Global spread of dengue virus types: mapping the 70 year history |
Q56766779 | Global spread of epidemic dengue: the influence of environmental change |
Q35993466 | HLA Class I Supertype Associations With Clinical Outcome of Secondary Dengue Virus Infections in Ethnic Thais |
Q40569492 | HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. |
Q40293331 | HLA-A*01 allele: a risk factor for dengue haemorrhagic fever in Brazil's population |
Q35057781 | HLA-A*33:01 as protective allele for severe dengue in a population of Filipino children |
Q40409069 | Heat shock effect upon dengue virus replication into U937 cells. |
Q34763787 | Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic |
Q40152182 | High Anti-Dengue Virus Activity of the OAS Gene Family Is Associated With Increased Severity of Dengue |
Q27481682 | High Pro-Inflammatory Cytokine Secretion and Loss of High Avidity Cross-Reactive Cytotoxic T-Cells during the Course of Secondary Dengue Virus Infection |
Q29618174 | High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever |
Q28486302 | High content screening of a kinase-focused library reveals compounds broadly-active against dengue viruses |
Q33419779 | High producing tumor necrosis factor alpha gene alleles in protection against severe manifestations of dengue |
Q39799030 | High rate of unrecognized dengue virus infection in parts of the rainforest region of Nigeria. |
Q33877767 | High-dimensional CyTOF analysis of dengue virus-infected human DCs reveals distinct viral signatures |
Q35665847 | High-resolution analysis of intrahost genetic diversity in dengue virus serotype 1 infection identifies mixed infections |
Q40147299 | Higher levels of dengue-virus-specific IgG and IgA during pre-defervescence associated with primary dengue hemorrhagic fever |
Q27488302 | Highly Sensitive Detection of Dengue Virus Nucleic Acid in Samples from Clinically Ill Patients |
Q36096412 | Honokiol, a Lignan Biphenol Derived from the Magnolia Tree, Inhibits Dengue Virus Type 2 Infection |
Q27482207 | Host Gene Expression Profiling of Dengue Virus Infection in Cell Lines and Patients |
Q38002407 | Host genetic susceptibility to severe dengue infection |
Q37793734 | How Innate Immune Mechanisms Contribute to Antibody-Enhanced Viral Infections |
Q33853984 | How season and serotype determine dengue transmissibility |
Q26314609 | Human antibody response to dengue virus: implications for dengue vaccine design |
Q25161212 | Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus |
Q40585577 | Human dendritic cells as targets of dengue virus infection |
Q27468843 | Human heme oxygenase 1 is a potential host cell factor against dengue virus replication |
Q37995555 | Human poly- and cross-reactive anti-viral antibodies and their impact on protection and pathology |
Q24658429 | Humanized mice show clinical signs of dengue fever according to infecting virus genotype |
Q47558315 | Humoral Immune Responses Against Zika Virus Infection and the Importance of Preexisting Flavivirus Immunity |
Q29994510 | Humoral cross-reactivity between Zika and dengue viruses: implications for protection and pathology |
Q27305770 | IFN-γ production depends on IL-12 and IL-18 combined action and mediates host resistance to dengue virus infection in a nitric oxide-dependent manner |
Q39034933 | IL-22 modulates IL-17A production and controls inflammation and tissue damage in experimental dengue infection |
Q62485484 | Identification of Broad-Spectrum Antiviral Compounds by Targeting Viral Entry |
Q26694068 | Identification of RNA Binding Proteins Associated with Dengue Virus RNA in Infected Cells Reveals Temporally Distinct Host Factor Requirements |
Q35807844 | Identification of clinical factors associated with severe dengue among Thai adults: a prospective study |
Q39781949 | Identification of mutations in a candidate dengue 4 vaccine strain 341750 PDK20 and construction of a full-length cDNA clone of the PDK20 vaccine candidate |
Q100428036 | Identification of the phytobioactive Polygonum cuspidatum as an antiviral source for restricting dengue virus entry |
Q33438726 | IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity |
Q37584342 | Imino sugar glucosidase inhibitors as broadly active anti-filovirus agents |
Q27490592 | Immature Dengue Virus: A Veiled Pathogen? |
Q35179653 | Immature dengue virus is infectious in human immature dendritic cells via interaction with the receptor molecule DC-SIGN. |
Q33430763 | Immune Response to Dengue Virus Infection in Pediatric Patients in New Delhi, India--Association of Viremia, Inflammatory Mediators and Monocytes with Disease Severity |
Q38059915 | Immune evasion strategies of flaviviruses |
Q37901360 | Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms |
Q34261827 | Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection |
Q34165624 | Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. |
Q33841915 | Immunological and viral determinants of dengue severity in hospitalized adults in Ha Noi, Viet Nam. |
Q51131051 | Immunological serotype interactions and their effect on the epidemiological pattern of dengue. |
Q35613349 | Immunology and immunopathogenesis of dengue disease |
Q39410861 | Immunopathogenesis Versus Protection in Dengue Virus Infections |
Q27468884 | Impact of dengue virus (DENV) co-infection on clinical manifestations, disease severity and laboratory parameters |
Q38157106 | Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques |
Q38896966 | Impedimetric cell-based biosensor for real-time monitoring of cytopathic effects induced by dengue viruses |
Q27478084 | Improved Molecular Detection of Dengue Virus Serotype 1 Variants |
Q51733262 | Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4. |
Q26314599 | Improving dengue virus capture rates in humans and vectors in Kamphaeng Phet Province, Thailand, using an enhanced spatiotemporal surveillance strategy |
Q30250977 | In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination |
Q40309971 | Incidence and seroprevalence of dengue virus infections in Australian travellers to Asia. |
Q39495783 | Induced autophagy reduces virus output in dengue infected monocytic cells |
Q37500519 | Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccine |
Q40307795 | Infection and activation of human peripheral blood monocytes by dengue viruses through the mechanism of antibody-dependent enhancement. |
Q27469687 | Infection of human cells by dengue virus is modulated by different cell types and viral strains |
Q27485321 | Infection-Enhancing and -Neutralizing Activities of Mouse Monoclonal Antibodies against Dengue Type 2 and 4 Viruses Are Controlled by Complement Levels |
Q30396651 | Influenza and dengue virus co-infection impairs monocyte recruitment to the lung, increases dengue virus titers, and exacerbates pneumonia |
Q37347305 | Inhibition of Polyamine Biosynthesis Is a Broad-Spectrum Strategy against RNA Viruses |
Q90024871 | Inhibition of dengue virus replication in monocyte-derived dendritic cells by vivo-morpholino oligomers |
Q36228889 | Innate immune responses to dengue virus |
Q26314406 | Interaction of a dengue virus NS1-derived peptide with the inhibitory receptor KIR3DL1 on natural killer cells |
Q34633606 | International dispersal of dengue through air travel: importation risk for Europe |
Q39624994 | Intra-genotypic variation of predominant genotype II strains of dengue type-3 virus isolated during different epidemics in Thailand from 1973 to 2001. |
Q91605068 | Intra-host growth kinetics of dengue virus in the mosquito Aedes aegypti |
Q34671059 | Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes |
Q40528042 | Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity |
Q38870485 | Investigational drugs in early development for treating dengue infection. |
Q90353798 | Isolation and molecular characterization of dengue virus clinical isolates from pediatric patients in New Delhi |
Q33597509 | Isolation of dengue virus from the upper respiratory tract of four patients with dengue fever. |
Q38779406 | Issues in contemporary and potential future molecular diagnostics for dengue. |
Q30395396 | Issues related to recent dengue vaccine development |
Q115204511 | Ivermectin Accelerates Circulating Nonstructural Protein 1 (NS1) Clearance in Adult Dengue Patients: A Combined Phase 2/3 Randomized Double-blinded Placebo Controlled Trial |
Q40374538 | JNK phosphorylation, induced during dengue virus infection, is important for viral infection and requires the presence of cholesterol |
Q38618056 | Key concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates? |
Q33394239 | Kinetics of plasma viremia and soluble nonstructural protein 1 concentrations in dengue: differential effects according to serotype and immune status |
Q28476805 | Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue |
Q33424504 | Laboratory-confirmed Dengue in Children in Three Regional Hospitals in the Philippines in 2009-2010. |
Q35146621 | Lack of clinical manifestations in asymptomatic dengue infection is attributed to broad down-regulation and selective up-regulation of host defence response genes |
Q37223621 | Larval Temperature-Food Effects on Adult Mosquito Infection and Vertical Transmission of Dengue-1 Virus |
Q36615111 | Lessons from malaria control to help meet the rising challenge of dengue |
Q27315772 | Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification |
Q40418273 | Limited replication of yellow fever 17DD and 17D-Dengue recombinant viruses in rhesus monkeys |
Q40508579 | Lineage extinction and replacement in dengue type 1 virus populations are due to stochastic events rather than to natural selection |
Q36396156 | Liposome-mediated delivery of iminosugars enhances efficacy against dengue virus in vivo |
Q33743890 | Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination |
Q33380611 | Liver injury caused by antibodies against dengue virus nonstructural protein 1 in a murine model |
Q34160073 | Liver involvement associated with dengue infection in adults in Vietnam |
Q35105926 | Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2 |
Q35763159 | Lower Low-Density Lipoprotein Cholesterol Levels Are Associated with Severe Dengue Outcome |
Q34629343 | Mapping the interactions of dengue virus NS1 protein with human liver proteins using a yeast two-hybrid system: identification of C1q as an interacting partner |
Q34025762 | Maternal and perinatal outcomes of dengue in PortSudan, Eastern Sudan |
Q35097469 | Maternal antibody and viral factors in the pathogenesis of dengue virus in infants |
Q92162622 | Mathematics of dengue transmission dynamics: Roles of vector vertical transmission and temperature fluctuations |
Q24570135 | Maturation of dengue virus nonstructural protein 4B in monocytes enhances production of dengue hemorrhagic fever-associated chemokines and cytokines |
Q34306877 | Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop |
Q34088956 | Memory CD8+ T cells from naturally acquired primary dengue virus infection are highly cross-reactive |
Q36026358 | Meta-Analysis of Dengue Severity during Infection by Different Dengue Virus Serotypes in Primary and Secondary Infections |
Q41722923 | Meta-analysis of biomarkers for severe dengue infections. |
Q35935426 | Metabolomics-Based Discovery of Small Molecule Biomarkers in Serum Associated with Dengue Virus Infections and Disease Outcomes |
Q56395792 | Methods to discriminate primary from secondary dengue during acute symptomatic infection |
Q28742358 | Microevolution and virulence of dengue viruses |
Q38247016 | Micronutrients and dengue |
Q35009344 | Minimal within-host dengue models highlight the specific roles of the immune response in primary and secondary dengue infections |
Q27468903 | Miscarriage following dengue virus 3 infection in the first six weeks of pregnancy of a dengue virus-naive traveller returning from Bali to Italy, April 2016 |
Q26310760 | Modeling Mosquito-Borne Disease Spread in U.S. Urbanized Areas: The Case of Dengue in Miami |
Q57092750 | Modeling the Heterogeneity of Dengue Transmission in a City |
Q35082837 | Models of the impact of dengue vaccines: a review of current research and potential approaches |
Q54217627 | Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection. |
Q90396144 | Molecular & serological study of dengue virus-infected patients attending a tertiary hospital of Dhaka city, Bangladesh (2013 to 2016) |
Q64063103 | Molecular characterization of dengue virus reveals regional diversification of serotype 2 in Colombia |
Q40141583 | Molecular characterization of the 17D-204 yellow fever vaccine |
Q35716609 | Molecular detection and typing of dengue viruses from archived tissues of fatal cases by rt-PCR and sequencing: diagnostic and epidemiologic implications |
Q27869771 | Molecular detection of Zika virus in blood and RNA load determination during the French Polynesian outbreak |
Q40564210 | Molecular evolution and phylogeny of dengue type 4 virus in the Caribbean. |
Q38045381 | Molecular mechanisms involved in antibody-dependent enhancement of dengue virus infection in humans |
Q27488337 | Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection |
Q27489123 | Monoclonal antibody to dengue capsid protein: its application in dengue studies |
Q24684689 | Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention |
Q24655645 | Mosquito Saliva Increases Endothelial Permeability in the Skin, Immune Cell Migration, and Dengue Pathogenesis during Antibody-Dependent Enhancement |
Q27010151 | Mouse models to study dengue virus immunology and pathogenesis |
Q27477548 | Murine Model for Dengue Virus-Induced Lethal Disease with Increased Vascular Permeability |
Q35880177 | Myanmar dengue outbreak associated with displacement of serotypes 2, 3, and 4 by dengue 1. |
Q55648073 | NS1 Antigenemia and Viraemia Load: Potential Markers of Progression to Dengue Fatal Outcome? |
Q24194181 | NS1 antigen detecting assays for diagnosing acute dengue infection in people living in or returning from endemic countries |
Q35034151 | Natural, persistent oscillations in a spatial multi-strain disease system with application to dengue |
Q29618172 | Neutralization and antibody-dependent enhancement of dengue viruses |
Q50099498 | Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein |
Q38093249 | New development in the diagnosis of dengue infections |
Q35491639 | Next-generation dengue vaccines: novel strategies currently under development |
Q57454669 | Nonalcoholic fatty liver disease is associated with increased hemoconcentration, thrombocytopenia, and longer hospital stay in dengue-infected patients with plasma leakage |
Q37672305 | Novel Genetic and Molecular Tools for the Investigation and Control of Dengue Virus Transmission by Mosquitoes |
Q34472346 | Novel antiviral activity of baicalein against dengue virus |
Q34583461 | Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase |
Q30390721 | Observed and projected drivers of emerging infectious diseases in Europe |
Q36666340 | Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). |
Q52593443 | Operational utility of the reverse-transcription recombinase polymerase amplification for detection of dengue virus. |
Q27469986 | Optimized diagnosis of acute dengue fever in Swedish travelers by a combination of reverse transcription-PCR and immunoglobulin M detection |
Q29619585 | Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever |
Q27472938 | Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes |
Q38636217 | Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development |
Q37851212 | Partial maturation: an immune-evasion strategy of dengue virus? |
Q58997716 | Pathogenesis of Dengue Haemorrhagic Fever and Its Impact on Case Management |
Q26766198 | Pathogenesis of Dengue: Dawn of a New Era |
Q28729784 | Patterns of cellular immunity associated with experimental infection with rDEN2Δ30 (Tonga/74) supports its suitability as a human DENV challenge strain |
Q35097474 | Patterns of gene transcript abundance in the blood of children with severe or uncomplicated dengue highlight differences in disease evolution and host response to dengue virus infection |
Q33702837 | Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever |
Q39017020 | Peptide inhibitors against dengue virus infection. |
Q64236704 | Perspective: The promises of a holistic view of proteins-impact on antibody engineering and drug discovery |
Q27490989 | Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4 30-4995 in Healthy Adult Volunteers |
Q39835610 | Phenotypic analysis of dengue virus isolates associated with dengue fever and dengue hemorrhagic fever for cellular attachment, replication and interferon signaling ability |
Q39472973 | Phenotypic and genotypic characterization of dengue virus isolates differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome |
Q27486912 | Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever |
Q98906699 | Phosphoproteomic analysis of dengue virus infected U937 cells and identification of pyruvate kinase M2 as a differentially phosphorylated phosphoprotein |
Q34611164 | Phylodynamic analysis of the emergence and epidemiological impact of transmissible defective dengue viruses |
Q40532518 | Phylogeography and molecular evolution of dengue 2 in the Caribbean basin, 1981-2000. |
Q50255448 | Plasma leakage in dengue haemorrhagic fever |
Q33194696 | Policymakers’ views on dengue fever/dengue haemorrhagic fever and the need for dengue vaccines in four southeast Asian countries |
Q37572667 | Population structure of the dengue viruses, Aragua, Venezuela, 2006-2007. Insights into dengue evolution under hyperendemic transmission |
Q30364184 | Porcine reproductive and respiratory syndrome (PRRS): an immune dysregulatory pandemic. |
Q66679798 | Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes |
Q36718596 | Potential of ancestral sylvatic dengue-2 viruses to re-emerge |
Q34080726 | Potential opportunities and perils of imperfect dengue vaccines. |
Q37609595 | Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses |
Q21146686 | Predicting outcome from dengue |
Q55084344 | Prediction and prevention of urban arbovirus epidemics: A challenge for the global virology community. |
Q26315571 | Presence of three dengue serotypes in Ouagadougou (Burkina Faso): research and public health implications |
Q33357597 | Preventive transfusion in dengue shock syndrome–is it necessary? |
Q37007528 | Primary dengue haemorrhagic fever in patients from northeast of Brazil is associated with high levels of interferon-β during acute phase |
Q36720238 | Primary dengue virus infections induce differential cytokine production in Mexican patients. |
Q34345965 | Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans |
Q37010921 | Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice |
Q40037516 | Progress and Challenges Towards Point-of-Care Diagnostic Development for Dengue. |
Q36825107 | Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach |
Q35009119 | Progress towards a dengue vaccine |
Q30235612 | Prospects for a Zika Virus Vaccine |
Q29619608 | Prospects for a dengue virus vaccine |
Q27486945 | Protective and Enhancing HLA Alleles, HLA-DRB1*0901 and HLA-A*24, for Severe Forms of Dengue Virus Infection, Dengue Hemorrhagic Fever and Dengue Shock Syndrome |
Q38731663 | Protective and immunological behavior of chimeric yellow fever dengue vaccine |
Q39505039 | Proteomic analysis of an Aedes albopictus cell line infected with Dengue serotypes 1 and 3 viruses |
Q30203504 | Prototype early warning systems for vector-borne diseases in Europe |
Q35022653 | Public versus personal serotypes of a viral quasispecies. |
Q24727667 | Quantitative competitive reverse transcription-PCR for quantification of dengue virus RNA |
Q40290385 | Quasispecies of dengue virus |
Q33338951 | Questions on viral population biology to complete dengue puzzle |
Q27472702 | Randomized, Placebo-Controlled Trial of Nonpegylated and Pegylated Forms of Recombinant Human Alpha Interferon 2a for Suppression of Dengue Virus Viremia in Rhesus Monkeys |
Q36992653 | Re-evaluation of the pathogenic roles of nonstructural protein 1 and its antibodies during dengue virus infection |
Q27477646 | Recent Advances in Deciphering Viral and Host Determinants of Dengue Virus Replication and Pathogenesis |
Q92859173 | Recent advances in understanding dengue |
Q40197722 | Receptor-activated human α2-macroglobulin interacts with the envelope protein of dengue virus and protects virions from temperature-induced inactivation through multivalent binding |
Q92471671 | Reciprocal immune enhancement of dengue and Zika virus infection in human skin |
Q39028302 | Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity |
Q27469474 | Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys |
Q37108706 | Reconstructing historical changes in the force of infection of dengue fever in Singapore: implications for surveillance and control |
Q37109553 | Reduced risk of disease during postsecondary dengue virus infections |
Q58759739 | Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning |
Q34374905 | Refining the global spatial limits of dengue virus transmission by evidence-based consensus |
Q34087489 | Relationship between nonstructural protein 1 detection and plasma virus load in Dengue patients |
Q36234359 | Replacement of pr gene with Japanese encephalitis virus pr using reverse genetics reduces antibody-dependent enhancement of dengue virus 2 infection |
Q41926510 | Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding. |
Q34058747 | Report of an NIAID workshop on dengue animal models |
Q27022905 | Return of epidemic dengue in the United States: implications for the public health practitioner |
Q35905785 | Revealing the molecular signatures of host-pathogen interactions. |
Q37390846 | Reverse transcription loop-mediated isothermal amplification (RT-LAMP) for diagnosis of dengue |
Q34640272 | Review article: Research on dengue during World War II revisited |
Q38174301 | Revisiting dengue virus-host cell interaction: new insights into molecular and cellular virology |
Q36181531 | Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults |
Q59790650 | Role of NS1 antibodies in the pathogenesis of acute secondary dengue infection |
Q24655655 | Role of dendritic cells in antibody-dependent enhancement of dengue virus infection |
Q92392677 | Role of microRNAs in antiviral responses to dengue infection |
Q26860307 | Role of microparticles in dengue virus infection and its impact on medical intervention strategies |
Q33393510 | Role of the chemokine receptors CCR1, CCR2 and CCR4 in the pathogenesis of experimental dengue infection in mice |
Q28475368 | Roles of small GTPase Rac1 in the regulation of actin cytoskeleton during dengue virus infection |
Q35131443 | Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants |
Q37330751 | Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development |
Q45017668 | Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005. |
Q54209744 | Screening of melatonin, α-tocopherol, folic acid, acetyl-L-carnitine and resveratrol for anti-dengue 2 virus activity. |
Q36382589 | Sculpting humoral immunity through dengue vaccination to enhance protective immunity |
Q27481677 | Secreted NS1 of Dengue Virus Attaches to the Surface of Cells via Interactions with Heparan Sulfate and Chondroitin Sulfate E |
Q24558700 | Selection for virulent dengue viruses occurs in humans and mosquitoes |
Q34855189 | Sequential waves of gene expression in patients with clinically defined dengue illnesses reveal subtle disease phases and predict disease severity |
Q39302764 | Serological characterization of dengue virus infections observed among dengue hemorrhagic fever/dengue shock syndrome cases in upper Myanmar |
Q27473050 | Serological differentiation of infections with dengue virus serotypes 1 to 4 by using recombinant antigens |
Q40052267 | Serological, molecular and clinical correlates of dengue from a tertiary care centre in Chennai, India |
Q27477501 | Serotype 1-Specific Monoclonal Antibody-Based Antigen Capture Immunoassay for Detection of Circulating Nonstructural Protein NS1: Implications for Early Diagnosis and Serotyping of Dengue Virus Infections |
Q26314515 | Serotype influences on dengue severity: a cross-sectional study on 485 confirmed dengue cases in Vitória, Brazil |
Q27491001 | Serotype-Specific Differences in the Risk of Dengue Hemorrhagic Fever: An Analysis of Data Collected in Bangkok, Thailand from 1994 to 2006 |
Q28289980 | Serotype-specific entry of dengue virus into liver cells: identification of the 37-kilodalton/67-kilodalton high-affinity laminin receptor as a dengue virus serotype 1 receptor |
Q27468816 | Serum Procalcitonin and Peripheral Venous Lactate for Predicting Dengue Shock and/or Organ Failure: A Prospective Observational Study |
Q97549435 | Serum chymase levels correlate with severe dengue warning signs and clinical fluid accumulation in hospitalized pediatric patients |
Q58779698 | Serum fatty acids and progression from dengue fever to dengue haemorrhagic fever/dengue shock syndrome |
Q36073685 | Serum levels of soluble vascular cell adhesion molecules may correlate with the severity of dengue virus-1 infection in adults |
Q34500818 | Serum proteome and cytokine analysis in a longitudinal cohort of adults with primary dengue infection reveals predictive markers of DHF. |
Q57731812 | Severe dengue and pregnancy: a review of data from the Rio de Janeiro, Brazil, surveillance information system |
Q39264890 | Signaling by Antibodies: Recent Progress |
Q54988577 | Simulation Model for Dynamics of Dengue with Innate and Humoral Immune Responses. |
Q33709817 | Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control |
Q40140549 | Single point mutations in the helicase domain of the NS3 protein enhance dengue virus replicative capacity in human monocyte-derived dendritic cells and circumvent the type I interferon response. |
Q34702394 | Single-reaction, multiplex, real-time rt-PCR for the detection, quantitation, and serotyping of dengue viruses |
Q40469577 | Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. |
Q33906261 | Space-time analysis of hospitalised dengue patients in rural Thailand reveals important temporal intervals in the pattern of dengue virus transmission |
Q29353638 | Spatial Distribution of Epidemiological Cases of Dengue Fever in Suriname, 2001-2012. |
Q27487319 | Spatial and Temporal Clustering of Dengue Virus Transmission in Thai Villages |
Q38876970 | Spatial patterns of dengue cases in Brazil |
Q27488364 | Structural Insights into the Mechanisms of Antibody-Mediated Neutralization of Flavivirus Infection: Implications for Vaccine Development |
Q93162327 | Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody |
Q38959153 | Sub-genomic RNA of defective interfering (D.I.) dengue viral particles is replicated in the same manner as full length genomes |
Q39576880 | Substitution of the precursor peptide prevents anti-prM antibody-mediated antibody-dependent enhancement of dengue virus infection |
Q56355933 | Successful Vaccines |
Q27485468 | Superior infectivity for mosquito vectors contributes to competitive displacement among strains of dengue virus |
Q38745464 | Suppressive Effects of the Site 1 Protease (S1P) Inhibitor, PF-429242, on Dengue Virus Propagation |
Q27491097 | Sylvatic Dengue Viruses Share the Pathogenic Potential of Urban/Endemic Dengue Viruses |
Q34500910 | Synchrony of sylvatic dengue isolations: a multi-host, multi-vector SIR model of dengue virus transmission in Senegal |
Q47136667 | TLR2/MyD88 pathway-dependent regulation of dendritic cells by dengue virus promotes antibody-dependent enhancement via Th2-biased immunity |
Q36118259 | Targeted mutagenesis as a rational approach to dengue virus vaccine development |
Q90319214 | Targeting viral entry as a strategy for broad-spectrum antivirals |
Q92593979 | Temperature impacts on dengue emergence in the United States: Investigating the role of seasonality and climate change |
Q36192685 | Temperature-dependent production of pseudoinfectious dengue reporter virus particles by complementation |
Q34075136 | The 2012 Madeira dengue outbreak: epidemiological determinants and future epidemic potential |
Q26995782 | The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response |
Q27491317 | The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1 |
Q37073267 | The Emerging Duck Flavivirus Is Not Pathogenic for Primates and Is Highly Sensitive to Mammalian Interferon Antiviral Signaling |
Q39119333 | The Influence of Spatial Configuration of Residential Area and Vector Populations on Dengue Incidence Patterns in an Individual-Level Transmission Model |
Q99240509 | The RNA secondary structural variation in the cyclization elements of the dengue genome and the possible implications in pathogenicity |
Q39088502 | The Role and Function of Fcγ Receptors on Myeloid Cells |
Q33817714 | The Role of Heterotypic DENV-specific CD8+T Lymphocytes in an Immunocompetent Mouse Model of Secondary Dengue Virus Infection |
Q36217775 | The Significance of Prolonged and Saddleback Fever in Hospitalised Adult Dengue |
Q35427943 | The basic reproduction number R0 and effectiveness of reactive interventions during dengue epidemics: the 2002 dengue outbreak in Easter Island, Chile. |
Q56916580 | The battle between infection and host immune responses of dengue virus and its implication in dengue disease pathogenesis |
Q35594746 | The burden of dengue and chikungunya worldwide: implications for the southern United States and California |
Q24288879 | The changing epidemiology of dengue in China, 1990-2014: a descriptive analysis of 25 years of nationwide surveillance data |
Q28250383 | The complexity of antibody-dependent enhancement of dengue virus infection |
Q34048432 | The correlation between the presence of viremia and clinical severity in patients with enterovirus 71 infection: a multi-center cohort study |
Q42987133 | The dengue human challenge model: has the time come to accept this challenge? |
Q39540120 | The dengue virus conceals double-stranded RNA in the intracellular membrane to escape from an interferon response. |
Q38179175 | The dengue virus non-structural 1 protein: risks and benefits |
Q28478345 | The early clinical features of dengue in adults: challenges for early clinical diagnosis |
Q40109065 | The effect of Wolbachia on dengue dynamics in the presence of two serotypes of dengue: symmetric and asymmetric epidemiological characteristics |
Q33680283 | The effects of tertiary and quaternary infections on the epidemiology of dengue |
Q34980736 | The future of dengue vaccines |
Q34903764 | The history and evolution of human dengue emergence |
Q40205673 | The human dengue challenge experience at the Walter Reed Army Institute of Research |
Q36132065 | The impact of transgenic mosquitoes on dengue virulence to humans and mosquitoes |
Q36612659 | The importance of hematopoietic progenitor cells in dengue. |
Q44170022 | The introduction of dengue follows transportation infrastructure changes in the state of Acre, Brazil: A network-based analysis. |
Q34542621 | The native Wolbachia symbionts limit transmission of dengue virus in Aedes albopictus |
Q37904027 | The pathogenesis of dengue |
Q38284671 | The relevance of dengue virus genotypes surveillance at country level before vaccine approval |
Q33954195 | The role of climate variability and change in the transmission dynamics and geographic distribution of dengue |
Q37713190 | The role of endothelial activation in dengue hemorrhagic fever and hantavirus pulmonary syndrome |
Q35496004 | The role of pre-existing cross-reactive antibodies in determining the efficacy of vaccination in humans: study protocol for a randomized controlled trial |
Q40568715 | The seasonal pattern of dengue in endemic areas: mathematical models of mechanisms |
Q26700076 | The tortoise or the hare? Impacts of within-host dynamics on transmission success of arthropod-borne viruses |
Q35069160 | The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein |
Q34431491 | Therapeutics for dengue: recommendations for design and conduct of early-phase clinical trials |
Q22305635 | Threat of dengue to blood safety in dengue-endemic countries |
Q50052067 | Tick-Borne Encephalitis Virus Vaccine-Induced Human Antibodies Mediate Negligible Enhancement of Zika Virus Infection InVitro and in a Mouse Model |
Q27469955 | Tick-Borne Langat/Mosquito-Borne Dengue Flavivirus Chimera, a Candidate Live Attenuated Vaccine for Protection against Disease Caused by Members of the Tick-Borne Encephalitis Virus Complex: Evaluation in Rhesus Monkeys and in Mosquitoes |
Q28266913 | Traitors of the immune system-enhancing antibodies in HIV infection: their possible implication in HIV vaccine development |
Q27468674 | Transcriptome meta-analysis reveals a dysregulation in extra cellular matrix and cell junction associated gene signatures during Dengue virus infection |
Q50117666 | Transcytosis Involvement in Transport System and Endothelial Permeability of Vascular Leakage during Dengue Virus Infection |
Q34147626 | Transient CD4/CD8 ratio inversion and aberrant immune activation during dengue virus infection |
Q55333503 | Transmission-clearance trade-offs indicate that dengue virulence evolution depends on epidemiological context. |
Q35876653 | Travel-related dengue virus infection, The Netherlands, 2006-2007. |
Q34787775 | Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus. |
Q37047163 | Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua |
Q38540058 | Trials and tribulations on the path to developing a dengue vaccine |
Q39565037 | Under-recognition and reporting of dengue in Cambodia: a capture-recapture analysis of the National Dengue Surveillance System |
Q94461357 | Under-the-Radar Dengue Virus Infections in Natural Populations of Aedes aegypti Mosquitoes |
Q39653165 | Unfolded protein response (UPR) gene expression during antibody-dependent enhanced infection of cultured monocytes correlates with dengue disease severity |
Q30409538 | Unusual dengue virus 3 epidemic in Nicaragua, 2009 |
Q39593503 | Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development |
Q37132070 | Use of a Rapid Test for Diagnosis of Dengue during Suspected Dengue Outbreaks in Resource-Limited Regions |
Q65054977 | Using Macaques to Address Critical Questions in Zika Virus Research. |
Q40457125 | Using dimension reduction to improve outbreak predictability of multistrain diseases. |
Q33586742 | Utility of warning signs in guiding admission and predicting severe disease in adult dengue |
Q37184768 | Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles |
Q37330748 | Vaccine-induced enhancement of viral infections. |
Q36161353 | Validation and Application of a Commercial Quantitative Real-Time Reverse Transcriptase-PCR Assay in Investigation of a Large Dengue Virus Outbreak in Southern Taiwan |
Q35141237 | Validation of an internally controlled one-step real-time multiplex RT-PCR assay for the detection and quantitation of dengue virus RNA in plasma |
Q36213311 | Variation in inflammatory/regulatory cytokines in secondary, tertiary, and quaternary challenges with dengue virus |
Q33910950 | Variation in vector competence for dengue viruses does not depend on mosquito midgut binding affinity. |
Q33413903 | Vascular events in viral hemorrhagic fevers: a comparative study of dengue and hantaviruses |
Q40303277 | Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement |
Q62485177 | Vector-borne transmission and evolution of Zika virus |
Q33652446 | Vertical transmission of Key West dengue-1 virus by Aedes aegypti and Aedes albopictus (Diptera: Culicidae) mosquitoes from Florida |
Q39629453 | Viral entry inhibitors block dengue antibody-dependent enhancement in vitro |
Q36082908 | Viral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysis |
Q35656099 | Viral resistance of MOGS-CDG patients implies a broad-spectrum strategy against acute virus infections |
Q60046445 | Viral-Induced Enhanced Disease Illness |
Q26746890 | Viremia and Clinical Presentation in Nicaraguan Patients Infected with Zika Virus, Chikungunya Virus, and Dengue Virus |
Q40267017 | Viremic profiles in asymptomatic and symptomatic chikungunya fever: a blood transfusion threat? |
Q27472941 | Virus Replication and Cytokine Production in Dengue Virus-Infected Human B Lymphocytes |
Q40222559 | Virus antibody dynamics in primary and secondary dengue infections |
Q27478050 | Virus-Induced Decline in Soluble Vascular Endothelial Growth Receptor 2 Is Associated with Plasma Leakage in Dengue Hemorrhagic Fever |
Q34675123 | Virus-specific differences in rates of disease during the 2010 Dengue epidemic in Puerto Rico |
Q47232816 | Vivo-morpholino oligomers strongly inhibit dengue virus replication and production. |
Q57168259 | What Does the Future Hold for Yellow Fever Virus? (II) |
Q40047862 | Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Risks of Incomplete Immunity to Dengue Virus Revealed by Vaccination |
Q38947779 | Within-host viral dynamics of dengue serotype 1 infection |
Q92647408 | Yellow fever control: current epidemiology and vaccination strategies |
Search more.